Pergamum AB and Cadila Pharmaceuticals Ltd. have entered a strategic collaboration to develop a novel treatment of infections with a unique targeting mechanism different from traditional antibiotics.   The two companies will collaborate on the preclinical and clinical development of a novel therapeutic peptide developed by Pergamum AB, at Cadila’s facilities in Ahmedabad, India. Cadila will be responsible for all costs related to development through Phase II and the two companies will share glob...